- Home
- IP vs ONC Comparison
IP vs ONC Comparison
Compare IP & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IP
- ONC
- Stock Information
- Founded
- IP 1898
- ONC 2010
- Country
- IP United States
- ONC Switzerland
- Employees
- IP N/A
- ONC N/A
- Industry
- IP Paper
- ONC Biotechnology: Pharmaceutical Preparations
- Sector
- IP Basic Materials
- ONC Health Care
- Exchange
- IP Nasdaq
- ONC Nasdaq
- Market Cap
- IP 28.7B
- ONC 31.5B
- IPO Year
- IP N/A
- ONC N/A
- Fundamental
- Price
- IP $46.60
- ONC $321.36
- Analyst Decision
- IP Buy
- ONC Strong Buy
- Analyst Count
- IP 7
- ONC 9
- Target Price
- IP $56.00
- ONC $335.78
- AVG Volume (30 Days)
- IP 5.3M
- ONC 414.0K
- Earning Date
- IP 07-31-2025
- ONC 08-06-2025
- Dividend Yield
- IP 3.97%
- ONC N/A
- EPS Growth
- IP N/A
- ONC N/A
- EPS
- IP N/A
- ONC N/A
- Revenue
- IP $21,934,000,000.00
- ONC $4,562,002,000.00
- Revenue This Year
- IP $46.14
- ONC $865.19
- Revenue Next Year
- IP $5.57
- ONC $21.12
- P/E Ratio
- IP N/A
- ONC N/A
- Revenue Growth
- IP 18.13
- ONC 47.33
- 52 Week Low
- IP $43.27
- ONC $170.99
- 52 Week High
- IP $60.36
- ONC $321.57
- Technical
- Relative Strength Index (RSI)
- IP 39.65
- ONC N/A
- Support Level
- IP $46.57
- ONC N/A
- Resistance Level
- IP $48.81
- ONC N/A
- Average True Range (ATR)
- IP 1.56
- ONC 0.00
- MACD
- IP -0.31
- ONC 0.00
- Stochastic Oscillator
- IP 14.99
- ONC 0.00
About IP International Paper Company
International Paper manufactures packaging products and cellulose fibers. It accounts for roughly one third of the North American corrugated packaging market. Though it has operations in Brazil, India, and China, more than three fourths of its sales come from North America. International Paper serves a variety of end markets, including industrial, consumer products, and manufacturing.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.